Trending Sources

Xconomy Special Report: 12 San Diego Tech Startup to Watch in 2017

Xconomy

View the Slideshow A little more than a year ago, amid a resurgence in San Diego’s software sector, Xconomy identified a baker’s dozen of local tech companies to watch in 2016. Four of the companies on this year’s list also reflect how San Diego’s tech and life sciences communities have been coming together in interesting ways.

San Diego Startups Raise $287M in Third Quarter, and Top 10 Deals

Xconomy

Venture Capital investments in San Diego startups fell by roughly a third during the three months that ended September 30, according to data released recently by Seattle-based PitchBook and the National Venture Capital Association. As Xconomy reported last week , third-quarter venture funding also slipped nationwide to $14.99

San Diego Innovation Economy Extended Gains in 2015: Connect Report

Xconomy

That’s according to a report being released today by Connect, the local nonprofit group focused on technology and entrepreneurship.

Q2 VC Funding Soars in San Diego (After Revisions), and Top 10 Deals

Xconomy

But the San Diego data was off. million in 19 companies in San Diego. million invested in 23 San Diego companies.

Santa Barbara, San Diego Tops On Per-Capita Venture Capital

socalTECH

San Diego-Carlsbad-San Marcos was number 7, with $36.6M in deals and 3.3 San Jose-Sunnyvale-Santa Clara; 2. READ MORE>>.

At “The Vine,” Developer Builds a Vertical Campus for Tech Startups

Xconomy

In San Diego, the Irvine Company provided the entire second floor of its Broadway Street building at no cost for the downtown EvoNexus incubator.

San Diego Sees Strong Cybersecurity Growth As Firms Seek Talent

Xconomy

San Diego’s cybersecurity workforce has grown by nearly 15 percent over the past two years, according to a study released today by the Cyber Center of Excellence, a nonprofit industry group created to boost cybersecurity jobs and technologies in the region. The center also asked the San Diego Regional Economic Development Corp.

Immunotherapy Clinical Tests Spur Hope, and Plenty of Headaches

Xconomy

Aduro reported in May that more dropouts than expected scuttled the trial. Blinding many studies is futile, say clinicians.

Study 32

San Diego, Irvine Tops For Engineering Job Demand, Says Report

socalTECH

Two, Southern California markets-- San Diego and Irvine --are among the top ares for engineering job demand, according to a report today.

Nervana’s $400M+ Buyout Reflects Key Tech Trend in Machine Learning

Xconomy

Nervana, which now has 48 employees, plans to remain in San Diego and operate under its own brand name.

14 for ’17: Key Clinical Data To Watch For Next Year (Part 2)

Xconomy

Editor’s note: Ben Fidler and Frank Vinluan contributed to this report.] We continue our look ahead to some of the clinical data due in 2017 that could shape healthcare practice and sway investor sentiment for years to come. Read more » Reprints | Share: UNDERWRITERS AND PARTNERS.

New U.S. “Roadmap” Lays Out Routes to Accelerate Robotic Technologies

Xconomy

His talk amounted to a state-of-the-industry report on robotics, and highlighted key findings of the 107-page update of the U.S.

IBM Watson Health Launches Imaging Effort for Cancer, Other Diseases

Xconomy

That means doctors should be able to use Watson to read and digest health records, lab results, radiology reports, and relevant medical literature.

IBM 36

BlackThorn Emerges With $40M, New Weapons Against Neuro Disorders

Xconomy

Today they’re finally shedding a little light on what they’ve been up to. Today, BlackThorn is making its first formal announcement. It’s similar here.

Study 29

All In One Place: A New Immuno-Oncology Trial Resource

Xconomy

As reporters, we find that frustrating. The infections were turbo-charging the immune system. Perhaps you do, too.

New Data Show Biogen, Ionis Drug Might Help More With Rare Spine Disease

Xconomy

But new data released this morning show that the therapy, known as nusinersen (Spinraza), could have a much broader reach. points.

Study 27

Notes From The JPM ’17 Vortex: Trump, Rainstorms & The Price You Pay

Xconomy

[ Editor’s note: Ben Fidler contributed to this report ] The week of frenetic data sharing, deal talking, and party hopping of the J.P. Morgan Healthcare Conference—and the events that have mushroomed around it—took a punch to the gut just as most attendees were wrapping up and checking their outbound flight status.

Press 14

Sony Slashes Staff At San Diego Game Studio

socalTECH

Sony has cut more than 50 employees in San Diego, at its Sony San Diego Studio , which develops videogames such as Kill Strain and MLB. According to reports , the layoffs are part of a wider cut in its videogaming operations which also included workers in London. READ MORE>>.

The Five Major Tech Trends of 2016

Xconomy

To augment and overcome physical distance, we are starting to use drones, virtual reality, and driverless cars. percent of digital buyers in the U.S.

Biogen Buys Ionis Spine Disease Drug For $75M, Eyes FDA Filing

Xconomy

Spinal muscular atrophy affects over 25,000 people in the U.S. and stops many of them from ever being able to walk.

Study 29

Social Fund-raising Website GoFundMe Buys Detroit Rival CrowdRise

Xconomy

Brad Damphousse and Andy Ballester founded GoFundMe in San Diego in 2010. They departed in 2015, after selling a majority stake to an investor group led by Accel and Technology Crossover Ventures that reportedly valued GoFundMe at $600 million. Financial terms were not disclosed in a statement issued Tuesday by GoFundMe.

Duchenne Lessons: Advocates For Rare Spinal Disease Have Eyes on FDA

Xconomy

Heather and Jessica Tomko will tell you that they’re nothing alike. They’ve got different interests, different tastes in movies, television, and music.

Bio Roundup: Trump’s Rx Silence, PCSK9 News, Amgen’s Migraines & More

Xconomy

president’s intent to make good on his angry campaign rhetoric on drug prices, while the Associated Press reported that naming-and-shaming—that is, Congress hauling executives into hearings and penning angry letters—certainly hasn’t done the trick. Speculation swirled this week around the incoming U.S.

Press 19

Despite Low Crop Prices, Corporate and VC Agtech Investments Soar

Xconomy

The increase in dollars flowing to agtech comes despite commodity prices that are down 65 percent from their 2013 peak, the report says.

Two San Diego Sites Rank Tops In Rising Social Networking Interest

socalTECH

Image courtesy Bigstock. READ MORE>>. social networking analysis pinterest experian skillwho stocktwits ranking

Study 13

Biotech Roundup: Hellos, Goodbyes, “Cures” Delays And Trial News

Xconomy

Our San Diego editor Bruce Bigelow penned a personal goodbye to entrepreneur Larry Bock, who died last week of pancreatic cancer at the age of 56. —South San Francisco-based Second Genome hired a new CEO and president. The week started on a reflective note. And perhaps most important, there was the U.S. Or not.

News 28

Trump’s Election Stunner: Tech and Life Sciences Leaders React

Xconomy

” Xconomy’s editors contributed to this report. Still processing what this will mean for technology, business, society, and humanity—I guess it’s going to take a while. In the meantime, here are 10 notable reactions from around the Xconomy network, mostly via Twitter. ” 2. That’s my plan.” ” 3.

The Xconomy Immuno-Oncology Resource: A Mid-ASH T Cell Update

Xconomy

Xconomy reported last week on the new use of these cells to treat multiple myeloma.

Bio Roundup: FDA Says No, PCSK9 Value Fight, CRISPR Intrigue & More

Xconomy

The CRISPR news this week doesn’t need a metaphor; the drama that MIT Technology Review reported can stand alone. — MIT Technology Review reported this week that a graduate student in the lab of Feng Zhang, Broad Institute gene-editing star, had accused the Broad of misleading the U.S. Talk about sacrifice.

Bio Roundup: RIP Roger Tsien, Novartis CAR-T Wheel, Zika News & More

Xconomy

Nobel Prize winner Roger Tsien, a UC San Diego chemist, passed away in Oregon this week. As the San Diego Union Tribune reported in 2013, Tsien (pictured) was also unafraid to shine the spotlight on what he considered suspect scientific approaches, even when espoused by legends like DNA co-discoverer James Watson.

Third-Quarter Report Shows Slowdown in VC Activity, & Top 10 Deals

Xconomy

Venture capital activity is gradually easing from last year’s peak, according to a new quarterly report put together by Seattle-based PitchBook and the National Venture Capital Association. deals (1,796 companies) during the third quarter that ended September 30, according to the inaugural “Venture Monitor” report released today.

Regulus Shares Crumble As FDA Halts Testing of Hepatitis C Drug

Xconomy

Regulus reported that a second serious case of jaundice, or a yellowing of the skin and eyes, in a Phase 1 study of RG-101.

Study 15

Pharma’s Productivity Problem: Finding More Blockbuster Drugs

Xconomy

recent Silicon Valley Bank report noted that large corporations have dramatically increased pre-clinical acquisitions in the last three years under the pressure of limited supply and competition from IPOs.  The authors made the point that, given the size of companies today, a single garden-variety blockbuster hardly moves the needle.

What Startups Can Do About Cyber Attacks

Xconomy

These statistics belie the common notion that cybercriminals attack only big businesses. Good Cybersecurity Program Matters. Understand the Risks.

New Leader at Intel Capital Adjusts Strategy as Global Summit Opens

Xconomy

The recent funding deals that Intel Capital laid out in San Diego Monday, on the first day of its 17th annual global summit, also reflect the strategic thinking of Wendell Brooks, who took the helm at Intel Capital about a year ago as longtime president Arvind Sodhani retired.

Biotech Roundup: Scangos’s Exit, Zafgen’s Shakeup, Jounce, Relypsa & More

Xconomy

—Bruce Bigelow profiled Dauntless Pharmaceuticals , a stealthy biotech company creator in San Diego forming single-drug startups. —San Francisco gene therapy startup Audentes Pharmaceuticals (NASDAQ: BOLD ) raised $75 million in an IPO , selling 5 million shares at $15 apiece, right in its projected range.

MEI Pharma Partners with Helsinn on Drug with Potential $464M Payoff

Xconomy

months in previously untreated elderly patients who received the drug.

Study 12

Bio Roundup: Theranos Cuts, Alnylam Stops, Nobel Eats Its Own & More

Xconomy

—The Institute for Clinical and Economic Review (ICER), whose drug-value analyses set the pharma industry’s teeth on edge , issued a new report on PD-1 inhibitors , part of the first wave of cancer immunotherapy drugs to be approved. In December we’ll gather in San Francisco to discuss the U.S. TOP STORIES.

Study 17

14 For ’17: Key Clinical Data to Watch For Next Year (Part 1)

Xconomy

[Editor’s note: Alex Lash and Frank Vinluan contributed to this report.] Tesaro (NASDAQ: TSRO ) reported data for a drug that, if regulators approve, could help fend off the recurrence of ovarian cancer. There were high profile successes in 2016. Read more » Reprints | Share: UNDERWRITERS AND PARTNERS.

Study 21

Acadia Drug Shows Early Promise in Treating Alzheimer’s Psychosis

Xconomy

San Diego-based Acadia (NASDAQ: ACAD ) reported that patients treated in an exploratory study with its drug pimavanserin showed a statistically significant reduction in psychosis compared against a group given a placebo. Investors cheered the news, boosting Acadia’s stock price 13.6 percent to $28.88 in trading Tuesday morning.